Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Phytronix and Agilent to Co-Market Phytronix LDTD Ion Source with Agilent Mass Spectrometers

Published: Wednesday, June 10, 2009
Last Updated: Wednesday, June 10, 2009
Bookmark and Share
The non-exclusive co-marketing agreement aims to promote the Phytronix Laser Diode Thermal Desorption Ion Source with Agilent mass spectrometers.

Phytronix Technologies Inc. and Agilent Technologies Inc. announced they have signed a non-exclusive co-marketing agreement to promote the Phytronix Laser Diode Thermal Desorption (LDTD) Ion Source with Agilent mass spectrometers.

The LDTD Ion Source, used with an Agilent MS/MS can offer ultra fast sample analysis for both quantitative and qualitative applications in high-throughput environments such as drug discovery processes (ADMET and DMPK), toxicology, forensics, food safety, and environmental applications.

The LDTD complements Agilent’s 1200 Series HPLC-Chip/MS. The latter provides on-line LC/MS at nanoflow rates that are well-suited to applications where sample amount is limited. The LDTD is based on a shotgun approach, which uses the separation power of the mass spectrometer for high throughput small molecule quantization in a myriad of applications.

Agilent and Phytronix have co-developed the interface between the LDTD and Agilent mass spectrometers to provide life science users with throughput that can exceed 20,000 samples per week.

Under the agreement, the companies will co-market the LDTD and Agilent mass spectrometer systems with each company responsible for its individual products. Agilent will sell and support its mass spectrometers and Phytronix will sell and support the LDTD and the interface between the LDTD and Agilent mass spectrometers. Each company will co-promote their products at industry tradeshows and conferences.

“The combination of the LDTD with Agilent mass spectrometers provides a powerful tool for life science researchers,” said Jean Lacoursiere, Phytronix’s President.

“In particular the LDTD combined with the new Agilent 6530 Accurate-Mass Q-TOF and 6460 Triple Quadrupole instruments provides researchers with exceptional sensitivity and analytical speed. This LDTD-Agilent mass spectrometer system allows, for example, pharmacokinetic studies in less than 10 minutes as well as enzyme inhibition trials in 18 minutes rather than the 10 hours presently required with current methods of analysis.”

Ken Miller, Global Sr. Marketing Manager for Mass Spectrometry at Agilent, added, “The Phytronix LDTD system will be very complementary to the Agilent nanoflow HPLC-Chip technology. The LDTD ion source offers some added capabilities such as a run-time of 4 seconds per sample for high throughput analysis. Many of our customers have asked for the integration of the Phytronix system with our 6000 Series LC/MS products, especially the Agilent 6400 Series Triple Quadrupole LC/MS/MS system.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Agilent Extends Agreement with PerkinElmer on Bioanalyzer Chips
PerkinElmer supplies chips for Agilent's popular 2100 Bioanalyzer system.
Thursday, January 21, 2016
Agilent Supports Inaugural Singapore-South Korea Symposium on Glycomics
Event follows collaboration to develop tools for analysis of biologics, vaccines.
Saturday, February 15, 2014
Agilent, Cell Line Genetics Collaborate
Companies to collaborate on high-throughput cell-line characterization services for regenerative medicine, cancer researchers.
Thursday, February 13, 2014
Agilent Joins Forces with Baylor College of Medicine
Collaboration will see Agilent and Baylor provide customized CGH microarrays for cancer, prenatal and postnatal research.
Thursday, November 14, 2013
Agilent and Seoul National University Hospital Collaborate
The strategic collaboration will focus on the development and verification of various biomarkers for the development of drugs, including narcotics, immune-suppressants and biomarkers.
Friday, October 18, 2013
Agilent Technologies to Separate into Two Public Companies
Life sciences, diagnostics and applied markets (LDA) that will retain the Agilent name, and the other company will be comprised of Agilent's electronic measurement (EM) products.
Monday, September 23, 2013
Agilent Technologies and SomaLogic Enter Agreement
The agreement will expand access to SomaLogic's unbiased protein biomarker discovery platform.
Tuesday, August 13, 2013
Agilent Technologies Announces Winner of Fifth Annual Early Career Professor Award
Assistant Professor at Northwestern Recognized for Cancer Diagnostics Research.
Friday, May 10, 2013
Agilent Technologies and Chungnam National University Announce Glycomics Research Initiatives
The collaboration hopes to develop biomarkers and new therapeutic antibodies to combat diseases such as cancer.
Tuesday, April 02, 2013
Agilent and Applied Proteomics Will Collaborate
Collaboration to maximize capabilities of highly multiplexed protein assays.
Friday, March 08, 2013
Agilent Technologies Collaborates with Gachon University
World-leading research laboratory at Gachon will have access to the latest technologies from Agilent and a beta test site for new solutions.
Monday, July 23, 2012
Agilent Technologies and Chungnam National University Collaborate to Further Glycomics Research
The university aims to identify and develop biomarkers for diseases.
Friday, August 26, 2011
Agilent Technologies Enters Second Phase of Collaboration to Map Human Proteome
Agilent’s collaboration with ISB and ETH Zurich for the mapping of the complete human proteome by mass spectrometry is enters its second phase.
Thursday, September 23, 2010
Agilent Updates Human Exon Target Enrichment Tool, Featuring Expressed Genome Content and Optimized Uniformity
The Latest SureSelect product to emerge from close collaboration with The Broad Institute.
Wednesday, August 25, 2010
Agilent and Los Alamos Develop First High-Throughput System to be Deployed at UCLA’s Global Bio Lab
Researchers are developing new tools for characterizing biological pathogens that could give rise to potentially deadly pandemics.
Thursday, June 11, 2009
Scientific News
New Insights into Gene Regulation
Researchers have solved the three-dimensional structure of a gene repression complex that is known to play a role in cancer.
Controlling RNA in Living Cells
Modular, programmable proteins can be used to track or manipulate gene expression.
Genetic Approach May Lead to New Treatments for Digestive Diseases
Researchers at UMass Medical School have identified a new molecular pathway critical for maintaining the smooth muscle tone that allows the passage of materials through the digestive system.
Fructose Alters Hundreds of Brain Genes
UCLA scientists report that diet rich in omega-3 fatty acids can reverse the damage.
DNA Barcodes Gone Wild
A team of researchers at University of Toronto’s Donnelly Centre and Sinai Health System’s Lunenfeld-Tanenbaum Research Institute (LTRI) has developed a new technology that can stitch together DNA barcodes inside a cell to simultaneously search amongst millions of protein pairs for protein interactions.
New Genetic Risk Factors for Myopia Discovered
Genes and environment determine short-sightedness.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
New Neurodevelopmental Syndrome Identified
Study pinpoints underlying genetic mutations, raising hopes for targeted therapies.
Uncovering How Some Breast Cancers Resist Treatment
A targeted therapy for triple-negative breast cancer (TNBC), the most aggressive form of breast cancer, has shown potential promise in a recently published study.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!